Wspolczesna Onkologia-Contemporary Oncology最新文献

{"title":"Correlation of PD-L1 expression with toxicities and response in oropharyngeal cancers treated with definitive chemoradiotherapy.","authors":"Smriti Srivastava,&nbsp;Madhup Rastogi,&nbsp;Ajeet Kumar Gandhi,&nbsp;Rohini Khurana,&nbsp;Rahat Hadi,&nbsp;Shantanu Sapru,&nbsp;Anoop Srivastava,&nbsp;Avinav Bharati,&nbsp;Nuzhat Husain,&nbsp;Surendra Prasad Mishra,&nbsp;Kamal Sahni","doi":"10.5114/wo.2022.118227","DOIUrl":"https://doi.org/10.5114/wo.2022.118227","url":null,"abstract":"<p><strong>Introduction: </strong>The programmed death receptor ligand 1 (PD-L1) is a cell-surface glycoprotein expressed in tumour cells (TCs) and is also upregulated in tumour infiltrating lymphocytes. The effect of PD-L1 expression on TCs and tumour-infiltrating lymphocytes (TILs) on acute radiation toxicity and response in oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy is less known.</p><p><strong>Material and methods: </strong>Squamous cell carcinoma of oropharynx with stage II-IVA (AJCC 8^th) were recruited in this prospective observational study. Definitive radiation therapy (RT) of 70 Gray in 35 fractions at 2 Gray per fraction, 5 fractions a week in 2 phases was delivered with concurrent chemotherapy (cisplatin 40 mg/m² weekly). Patients were assessed weekly for acute toxicities with Radiation Therapy Oncology Group criteria. Response assessment was done at 3 months post RT according to World Health Organization response assessment criteria. The programmed death receptor ligand 1 expression in TCs and TILs was correlated with acute toxicity and survival.</p><p><strong>Results: </strong>Of 51 patients, 20 (39.2%) had PD-L1 expression in TCs and 18 (35.3%) in TILs. Patients with PD-L1 expression in TCs had fewer grade ≥ 3 oral mucositis (25% vs. 58%; <i>p</i> = 0.02) and grade ≥ 3 dysphagia (25% vs. 55%; <i>p</i> = 0.046). The programmed death receptor ligand 1-tumour infiltrating lymphocytes positives had lower ≥ 3 grade oral mucositis (22% vs. 58%; <i>p</i> = 0.02) and ≥ 3 grade dysphagia (17% vs. 58%; <i>p</i> = 0.007). Two-year overall and progression-free survival rate for the PD-L1-tumour-positive vs. PD-L1-tumour-negative group was not different (<i>p</i> > 0.5).</p><p><strong>Conclusions: </strong>Positive PD-L1 expression is associated with fewer acute radiation toxicities, and this could be used as a potential biomarker.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/51/WO-26-47517.PMC9641626.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40466078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score.","authors":"Heba F Taha, Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, Ola M Elfarargy","doi":"10.5114/wo.2022.120592","DOIUrl":"10.5114/wo.2022.120592","url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.</p><p><strong>Material and methods: </strong>Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.</p><p><strong>Results: </strong>We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, <i>p</i>-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, <i>p</i>-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, <i>p</i>-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, <i>p</i>-value = 0.230).</p><p><strong>Conclusions: </strong>Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/48/WO-26-48040.PMC9641632.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40466079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver metastasis or a pseudocyst? A rare presentation of leiomyosarcoma's metastasis in the liver.","authors":"Adrian Bednarek,&nbsp;Julia Sołek,&nbsp;Konrad Szymczyk,&nbsp;Mikołaj Gwardys,&nbsp;Agnieszka Wierzchniewska-Ławska,&nbsp;Dorota Jesionek-Kupnicka,&nbsp;Marcin Braun,&nbsp;Hanna M Romańska","doi":"10.5114/wo.2022.124595","DOIUrl":"https://doi.org/10.5114/wo.2022.124595","url":null,"abstract":"<p><p>Gastrointestinal neoplasms most commonly metastasize to the liver, where they are typically found as solid and hypervascular lesions. Here, we describe a case of a 44-year-old man with a leiomyosarcoma of the rectum, who at the time of diagnosis presented with a small (5 mm in diameter) cyst-like lesion in the liver. Positron emission tomography demonstrated no increased metabolism in the area of the cyst, suggesting a benign character of the lesion. However, after 3 years, CT scans revealed enlargement of the cyst, and local surgical excision was performed. The results of histopathological examination of the resected material were consistent with metastatic leiomyosarcoma. Subsequently, the patient developed lung metastases and died within 2 years. Our case describes a very rare presentation of leiomyosarcoma's metastasis that led to an ill-fated misdiagnosis and dismal disease outcome.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/bf/WO-26-50024.PMC9933358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10762385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring of treatment with L-asparaginase in children with acute lymphoblastic leukaemia, with a focus on silent inactivation and its influence on the treatment outcome.","authors":"Malgorzata Czogala,&nbsp;Iwona Rogatko,&nbsp;Katarzyna Pawińska-Wąsikowska,&nbsp;Wojciech Czogała,&nbsp;Wioletta Bal,&nbsp;Małgorzata Ciebiera,&nbsp;Radosław Chaber,&nbsp;Agnieszka Chodała-Grzywacz,&nbsp;Grażyna Karolczyk,&nbsp;Krystyna Sztefko,&nbsp;Walentyna Balwierz,&nbsp;Szymon Skoczeń","doi":"10.5114/wo.2023.124972","DOIUrl":"https://doi.org/10.5114/wo.2023.124972","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to analyse the frequency of silent inactivation and allergic reaction to asparaginase (ASP) and its impact on treatment results in patients with lymphoblastic leukaemia.</p><p><strong>Material and methods: </strong>Seventy patients with acute lymphoblastic leukaemia treated with ASP were enrolled in the study. Asparaginase activity was monitored. The patients were switched to another ASP formulation after allergy or inactivation. The treatment results were analysed.</p><p><strong>Results: </strong>Silent inactivation of native <i>E. coli</i> ASP was diagnosed in 5 patients (7%) and allergy in 34 patients (49%), and these patients were switched to pegylated ASP (PEG-ASP). Silent inactivation of PEG-ASP occurred in 8 patients (23%) and allergy in 6 patients (17%). Eight children continued therapy with Erwinase, and 4 did not switch to Erwinase after inactivation of PEG-ASP. Allergy to Erwinase occurred in 2 patients (22%); there was no inactivation. No significant differences in outcome were found between the groups of patients with and without allergy or silent inactivation of ASP. Due to regular monitoring and switching to other ASP preparations after allergy or silent inactivation, therapeutic activity was ensured in almost all patients.</p><p><strong>Conclusions: </strong>Monitoring of ASP activity is crucial to recognize silent inactivation and to guarantee treatment effectiveness by switching to other ASP preparations.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/6b/WO-26-50127.PMC9933359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10765702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of inflammation biomarkers in differential diagnosis of pelvic tumours of ovarian origin: a single-centre observational study.","authors":"Victoria Psomiadou,&nbsp;Anastasia Prodromidou,&nbsp;Elpis Galati,&nbsp;Ioannis D Kostakis,&nbsp;Athanasios Maliaros,&nbsp;Ioannis Mamais,&nbsp;Nikolaos Blontzos,&nbsp;Fotios Lefkopoulos,&nbsp;Christos Iavazzo,&nbsp;George Vorgias","doi":"10.5114/wo.2021.105072","DOIUrl":"https://doi.org/10.5114/wo.2021.105072","url":null,"abstract":"<p><strong>Aim of the study: </strong>Our aim was to analyse the feasibility of white blood cell and platelet counts along with their ratios as a prognostic factor in patients who underwent surgery for ovarian mass.</p><p><strong>Material and methods: </strong>We retrospectively studied the patients admitted in the Department of Gynaecology due to adnexal mass. The potential association of the neutrophil-to-lymphocyte-ratio (NLR), neutrophil-to-monocyte (NMR), platelet-to-lymphocyte (PLR), lymphocyte-to-monocyte (LMR), monocyte-to-platelet, and malignancy was evaluated.</p><p><strong>Results: </strong>Patients with malignant tumours were found with significantly higher ratios of NLR (<i>p</i> < 0.001) and PLR (<i>p</i> < 0.001) and lower LMR ratio (<i>p</i> < 0.001) compared to those with benign tumours. Furthermore, higher lymphocyte count (<i>p</i> = 0.04) and platelet count (<i>p</i> = 0.004) were found in cancer patients when compared with borderline tumours. No significant variations were detected regarding white blood cell count (<i>p</i> = 0.238), NMR ratio (<i>p</i> = 0.28), platelet-to-neutrophil ratio (<i>p</i> = 0.12), and platelet-to-monocyte ratio (<i>p</i> = 0.34).</p><p><strong>Conclusions: </strong>Inflammation biomarker ratios can easily and inexpensive assist in distinguishing malignant ovarian tumours from benign ones.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/9f/WO-25-43726.PMC8063895.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose-rate brachytherapy for non-melanoma skin cancer using tailored custom moulds - a single-centre experience.","authors":"Concetta Laliscia, Taiusha Fuentes, Natalina Coccia, Roberto Mattioni, Franco Perrone, Fabiola Paiar","doi":"10.5114/wo.2021.104688","DOIUrl":"10.5114/wo.2021.104688","url":null,"abstract":"<p><strong>Aim of the study: </strong>The aim of this retrospective study was to analyse tumour control, toxicity, and aesthetic outcome of patients affected by non-melanoma skin cancer (NMSC) treated with 192 Ir high-dose-rate (HDR)-brachytherapy (BT) at the Division of Radiotherapy, University of Pisa.</p><p><strong>Material and methods: </strong>From January 2014 to December 2019 we treated 37 patients (median age 79 years; range 31-91 years) affected by NMSC, with the following histological subtypes: 62.2% basal cell carcinoma and 37.8% squamous cell carcinoma. We analysed 40 lesions with a depth ≤ 5 mm, located in 40.0% scalp, 17.5% nose, 25.0% face, and 17.5% ear, all treated with 192 Ir-based HDR-BT, using tailored custom moulds, with a median of 5 catheters (range, 1-9) spaced 1 cm apart. The most common fractionation scheme was 40 Gy in 8 daily fractions; the biological effective dose was 60 Gy.</p><p><strong>Results: </strong>The median follow-up was 25 months (range, 3-70 months). The 2-year local control rate was 90%. Common terminology criteria for adverse event (CTCAE vs. 5.0) G1 toxicities were dermatitis (52%), pain (25%), and ulceration (22%). The only G2 acute toxicities were dermatitis and ulceration. The most common G1 late toxicities were fibrosis (17%), atrophy (15%), and hypopigmentation (12%). No G3 or higher acute or late toxicity was reported. Excellent cosmetic results were observed in 65.0% of the lesions; only 1 case (2.5%) reported a poor cosmetic result.</p><p><strong>Conclusions: </strong>Surface mould HDR-BT is a safe, effective, and well tolerated treatment modality for NMSC and can be considered a good alternative, especially for elderly patients who are often unfit for surgery.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/90/WO-25-43572.PMC8063903.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrast-enhanced spectral mammography without and with a delayed image for diagnosing malignancy among mass lesions in dense breast.","authors":"Akmaral Serikovna Ainakulova,&nbsp;Zhamilya Zholdybay Zholdybay,&nbsp;Dilyara Radikovna Kaidarova,&nbsp;Natalya Igorevna Inozemtceva,&nbsp;Madina Orazaykyzy Gabdullina,&nbsp;Zhanar Kabdualievna Zhakenova,&nbsp;Alexandra Sergeevna Panina,&nbsp;Dias Kairatovich Toleshbayev,&nbsp;Jandos Mukhtarovich Amankulov","doi":"10.5114/wo.2021.105030","DOIUrl":"https://doi.org/10.5114/wo.2021.105030","url":null,"abstract":"<p><strong>Aim of the study: </strong>To analyse the diagnostic performance of contrast-enhanced spectral mammography (CESM) based on morphologic and enhancement patterns of mass lesions in dense breast using different protocols: CESM without delayed image and CESM with delayed image.</p><p><strong>Material and methods: </strong>A total of 151 informed women with suspicious for malignancy mass lesions in dense breast were included in this study. All of them underwent CESM using 2 protocols. A total of 155 lesions were pathomorphologically verified. We analysed morphologic patterns on low-energy (LE) images and recombined images (RI) by defining the shape, margin, and dynamic patterns based on delayed images.</p><p><strong>Results: </strong>The comparative analysis revealed that the shape and margins on RI were more significant than those on LE images. The dynamic indicators of CESM were found to be highly significant in dense breasts. The correlation between kinetic curve and histological results demonstrated that a persistent type of curve was common for benign lesions, accounting for 15/22 (68.1%); plateau and washout - for malignant lesions, accounting for 24/89 (26.9%) and 61/89 (68.5%), respectively. Delayed image leads to an increase of specificity up to 12.4%, which is statistically significant. The area under the curve (AUC) in CESM with delayed image is larger than that in CESM without delayed image (<i>p</i> < 0.01).</p><p><strong>Conclusions: </strong>CESM is sensitive for the differential diagnosis of breast lesions. CESM with delayed image has higher specificity than CESM without delayed image. Delayed images with plateau and washout are typical for malignancy.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/30/WO-25-43719.PMC8063896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of lung cancer.","authors":"Krishna Chaitanya Thandra,&nbsp;Adam Barsouk,&nbsp;Kalyan Saginala,&nbsp;John Sukumar Aluru,&nbsp;Alexander Barsouk","doi":"10.5114/wo.2021.103829","DOIUrl":"https://doi.org/10.5114/wo.2021.103829","url":null,"abstract":"<p><p>Lung cancer is the leading cause of global cancer incidence and mortality, accounting for an estimated 2 million diagnoses and 1.8 million deaths. Neoplasms of the lungs are the second most common cancer diagnosis in men and women (after prostate and breast cancer, respectively). With increasing access to tobacco and industrialization in developing nations, lung cancer incidence is rising globally. The average age of diagnosis is 70 years old. Men are twice as likely to be diagnosed with lung cancer, which largely reflects differences in tobacco consumption, although women may be more susceptible due to higher proportions of epidermal growth factor receptor mutations and the effects of oestrogen. African American men in the US are at the highest risk of lung cancer. Family history increases risk by 1.7-fold, with a greater risk among first-degree relatives. Tobacco smoking is the greatest preventable cause of death worldwide, accounting for up to 90% of lung cancer cases, and continued consumption is projected to increase global cancer incidence, particularly in developing nations such as China, Russia, and India. Second-hand smoke among children and spouses has likewise been implicated. Radon from natural underground uranium decay is the second leading cause of lung cancer in the developed world. Occupational hazards such as asbestos and environmental exposures such as air pollution, arsenic, and HIV and Tb infection have all been implicated in lung carcinogenesis, while cannabis smoking, electronic cigarettes, heated tobacco products, and COVID-19 have been hypothesized to increase risk.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/96/WO-25-43345.PMC8063897.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complexity of tumour angiogenesis based on recently described molecules.","authors":"Weronika Wiśniewska,&nbsp;Michał Kopka,&nbsp;Karolina Siemiątkowska,&nbsp;Marta Magdalena Fudalej,&nbsp;Aleksandra Sobiborowicz,&nbsp;Anna Maria Badowska-Kozakiewicz","doi":"10.5114/wo.2021.105075","DOIUrl":"https://doi.org/10.5114/wo.2021.105075","url":null,"abstract":"<p><p>Tumour angiogenesis is a crucial factor associated with tumour growth, progression, and metastasis. The whole process is the result of an interaction between a wide range of different molecules, influencing each other. Herein we summarize novel discoveries related to the less known angiogenic molecules such as galectins, pentraxin-3, Ral-interacting protein of 76 kDa (RLIP76), long non-coding RNAs (lncRNAs), B7-H3, and delta-like ligand-4 (DLL-4) and their role in the process of tumour angiogenesis. These molecules influence the most important molecular pathways involved in the formation of blood vessels in cancer, including the vascular endothelial growth factor (VEGF)-vascular endothelial growth factor receptor interaction (VEGFR), HIF1-a activation, or PI3K/Akt/mTOR and JAK-STAT signalling pathways. Increased expression of galectins, RLIP76, and B7H3 has been proven in several malignancies. Pentraxin-3, which appears to inhibit tumour angiogenesis, shows reduced expression in tumour tissues. Anti-angiogenic treatment based mainly on VEGF inhibition has proved to be of limited effectiveness, leading to the development of drug resistance. The newly discovered molecules are of great interest as a potential source of new anti-cancer therapies. Their role as targets for new drugs and as prognostic markers in neoplasms is discussed in this review.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/80/WO-25-43728.PMC8063899.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38838926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer paients.","authors":"Yermek Turgunov,&nbsp;Alina Ogizbayeva,&nbsp;Lyudmila Akhmaltdinova,&nbsp;Kayrat Shakeyev","doi":"10.5114/wo.2021.110051","DOIUrl":"https://doi.org/10.5114/wo.2021.110051","url":null,"abstract":"<p><strong>Aim of the study: </strong>In this pilot study lipopolysaccharide-binding protein (LBP) levels were assessed as a possible risk factor for development of systemic inflammatory response syndrome (SIRS) and infectious and inflammatory complications in colorectal cancer (CRC) patients after surgery.</p><p><strong>Material and methods: </strong>For LBP determination venous blood was taken 1 hour before the surgery and 72 hours after it. All patients were stratified by the presence or absence of acute bowel obstruction (ABO), SIRS and complications.</p><p><strong>Results: </strong>36 patients with CRC participated in the study. The LBP level before surgery was 879.8 ± 221.8 ng/ml (interquartile range (IQR) 749.3-1028.8); on the 3^rd day it was 766.5 ± 159.4 ng/ml (IQR 669.5-847.6), which was a statistically significant decrease (<i>p</i> = 0.004). A decrease in LBP level by more than 280 ng/ml increases the probability of SIRS and complications in operated CRC patients (OR 6.6, 95% CI: 1.1-40.9 and OR 12.0, 95% CI: 1.8-80.4, respectively). In patients with ABO in the presence of SIRS, the LBP value decreased more than in those without SIRS (<i>p</i> = 0.046).</p><p><strong>Conclusions: </strong>This study demonstrated that the LBP level in the operated CRC patients tends to decrease on the 3^rd day after surgery. A bigger decrease in LBP level increases the probability of SIRS and postoperative infectious and inflammatory complications. Therefore, further studies with larger numbers of patients are required.</p>","PeriodicalId":49354,"journal":{"name":"Wspolczesna Onkologia-Contemporary Oncology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/90/WO-25-45449.PMC8547177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}